Literature DB >> 10880056

Albuterol-induced downregulation of Gsalpha accounts for pulmonary beta(2)-adrenoceptor desensitization in vivo.

P A Finney1, M G Belvisi, L E Donnelly, T T Chuang, J C Mak, C Scorer, P J Barnes, I M Adcock, M A Giembycz.   

Abstract

The aim of the present study was to develop a chronic in vivo model of pulmonary beta(2)-adrenoceptor desensitization and to elucidate the nature and molecular basis of this state. Subcutaneous infusion of rats with albuterol for 7 days compromised the ability of albuterol, given acutely, to protect against acetylcholine-induced bronchoconstriction. The bronchoprotective effect of prostaglandin E(2), but not forskolin, was also impaired, indicating that the desensitization was heterologous and that the primary defect in signaling was upstream of adenylyl cyclase. beta(2)-Adrenoceptor density was reduced in lung membranes harvested from albuterol-treated animals, and this was associated with impaired albuterol-induced cyclic adenosine monophosphate (cAMP) accumulation and activation of cAMP-dependent protein kinase ex vivo. Gsalpha expression was reduced in the lung and tracheae of albuterol-treated rats, and cholera toxin-induced cAMP accumulation was blunted. Chronic treatment of rats with albuterol also increased cAMP phosphodiesterase activity and G protein-coupled receptor kinase-2, but the extent to which these events contributed to beta(2)-adrenoceptor desensitization was unclear given that forskolin was active in both groups of animals and that desensitization was heterologous. Collectively, these results indicate that albuterol effects heterologous desensitization of pulmonary Gs-coupled receptors in this model, with downregulation of Gsalpha representing a primary molecular etiology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880056      PMCID: PMC314356          DOI: 10.1172/JCI8374

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma.

Authors:  B J O'Connor; S L Aikman; P J Barnes
Journal:  N Engl J Med       Date:  1992-10-22       Impact factor: 91.245

Review 2.  Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors.

Authors:  E F Grady; S K Böhm; N W Bunnett
Journal:  Am J Physiol       Date:  1997-09

3.  Chronic isoproterenol administration causes altered beta adrenoceptor-Gs-coupling in guinea pig lung.

Authors:  V Nerme; T Abrahamsson; G Vauquelin
Journal:  J Pharmacol Exp Ther       Date:  1990-03       Impact factor: 4.030

4.  Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo.

Authors:  J C Mak; M Nishikawa; H Shirasaki; K Miyayasu; P J Barnes
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

5.  Activation-induced subcellular redistribution of Gs alpha.

Authors:  P B Wedegaertner; H R Bourne; M von Zastrow
Journal:  Mol Biol Cell       Date:  1996-08       Impact factor: 4.138

6.  Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in beta2-adrenoreceptor desensitization.

Authors:  J Seybold; R Newton; L Wright; P A Finney; N Suttorp; P J Barnes; I M Adcock; M A Giembycz
Journal:  J Biol Chem       Date:  1998-08-07       Impact factor: 5.157

7.  Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade.

Authors:  G Iaccarino; E D Tomhave; R J Lefkowitz; W J Koch
Journal:  Circulation       Date:  1998-10-27       Impact factor: 29.690

8.  Differential down-regulation of pulmonary beta 1- and beta 2-adrenoceptor messenger RNA with prolonged in vivo infusion of isoprenaline.

Authors:  M Nishikawa; J C Mak; H Shirasaki; P J Barnes
Journal:  Eur J Pharmacol       Date:  1993-10-15       Impact factor: 4.432

9.  Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma.

Authors:  D M Newnham; D G McDevitt; B J Lipworth
Journal:  Am J Med       Date:  1994-07       Impact factor: 4.965

10.  A comparison of beta-adrenergic receptors and in vitro relaxant responses to isoproterenol in asthmatic airway smooth muscle.

Authors:  T R Bai; J C Mak; P J Barnes
Journal:  Am J Respir Cell Mol Biol       Date:  1992-06       Impact factor: 6.914

View more
  23 in total

1.  Beta-agonist-associated reduction in RGS5 expression promotes airway smooth muscle hyper-responsiveness.

Authors:  Zhao Yang; Philip R Cooper; Gautam Damera; Indranil Mukhopadhyay; Hyeseon Cho; John H Kehrl; Reynold A Panettieri; Kirk M Druey
Journal:  J Biol Chem       Date:  2011-01-29       Impact factor: 5.157

Review 2.  New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.

Authors:  J K L Walker; R B Penn; N A Hanania; B F Dickey; R A Bond
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

3.  Construction of a cell model of β2-adrenoceptor downregulation.

Authors:  Hua Liu; Yun Chen; Jun Li; Weishuai Zhang; Songshi Ni
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

Review 4.  Regulation of mast cells by beta-agonists.

Authors:  Peter Peachell
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 5.  Regulation of heterotrimeric G protein signaling in airway smooth muscle.

Authors:  Raymond B Penn; Jeffrey L Benovic
Journal:  Proc Am Thorac Soc       Date:  2008-01-01

6.  Exploiting functional domains of GRK2/3 to alter the competitive balance of pro- and anticontractile signaling in airway smooth muscle.

Authors:  Deepak A Deshpande; Huandong Yan; Kok-Choi Kong; Brian C Tiegs; Sarah J Morgan; Tonio Pera; Reynold A Panettieri; Andrea D Eckhart; Raymond B Penn
Journal:  FASEB J       Date:  2013-10-16       Impact factor: 5.191

7.  Role of Airway Smooth Muscle in Inflammation Related to Asthma and COPD.

Authors:  Hiroaki Kume
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Chronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β(2) -adrenoceptors and exacerbates lung inflammation in mice.

Authors:  Rui Lin; Simone Degan; Barbara S Theriot; Bernard M Fischer; Ryan T Strachan; Jiurong Liang; Richard A Pierce; Mary E Sunday; Paul W Noble; Monica Kraft; Arnold R Brody; Julia K L Walker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

9.  A Controlled Trial of Inhaled Bronchodilators in Familial Dysautonomia.

Authors:  Bat-El Bar-Aluma; Ori Efrati; Horacio Kaufmann; Jose-Alberto Palma; Lucy Norcliffe-Kaufmann
Journal:  Lung       Date:  2017-12-12       Impact factor: 2.584

10.  The human near-term myometrial beta 3-adrenoceptor but not the beta 2-adrenoceptor is resistant to desensitisation after sustained agonist stimulation.

Authors:  C Rouget; M Breuiller-Fouché; F J Mercier; M J Leroy; C Loustalot; E Naline; R Frydman; T Croci; E J Morcillo; C Advenier; M Bardou
Journal:  Br J Pharmacol       Date:  2004-02-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.